Cybin, Inc. · NEO:HELP
Cybin — Investor Presentation (August 2026)
45 slides from Cybin's investor presentation, August 2026
Slide 1: Corporate Presentation: Helping Minds Heal
Corporate Presentation Helping Minds Heal August 2026 Nasdaq: HELP Cboe CA: HELP 1 1
Slide 2: Cautionary Statement
Cautionary Statement The information contained in this presentation has been prepared by Cybin Inc . and its affiliates (“Helus” or the “Company”), which operates as Helus Pharma and its respective affiliates . The information contained in this presentation : (a) is provided as at the date hereof, i
Slide 3: Leading the Development of Novel Serotonergic Agonists
Leading the Development of Novel Serotonergic Agonists (“NSAs”) 1,2 Two proprietary clinical programs, HLP003 and HLP 004, targeting major depressive disorder ("MDD") and 1 generalized anxiety disorder ("GAD") with positive Phase 2 safety and efficacy results Lead program HLP003 has been granted U.S
Slide 4: Executing on Our Innovative Pipeline to Enable a Paradigm Shift in Mental Health
Executing on Our Innovative Pipeline to Enable a Paradigm Shift in Mental Health PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 HLP003 Adjunctive • Q4 2026: Phase 3 Phase 3 study dosing underway Deuterated NSA treatment of APPROACH topline Granted FDA Breakthrough Therapy Designation (Oral)
Slide 5: Portfolio strategy expands addressable market and commercial opportunity
Portfolio strategy expands addressable market and commercial opportunity 5,6 Broaden addressable market & address Leverage portfolio and drive commercial comorbidities synergies Addressing overlapping needs in MDD and GAD HLP003 Build platform – Salesforce and distribution network – Reimbursement an
Slide 6: Strong IP Portfolio Supporting HLP003 and HLP004
Strong IP Portfolio Supporting HLP003 and HLP004 1,2,3 U.S. Exclusivity Timeline 5 Yr NCE Exclusivity + NDA 30 - Month Stay approval ~7.5 yrs 2041 P NCE exclusivity Granted Patent exclusivity ✓ Multilayered IP strategy ✓ Issued patents provide IP protection • Compositions and: until at least 2041 Or
Slide 7: Reducing Burden on Clinical Infrastructure
Reducing Burden on Clinical Infrastructure Interventional Psychiatry Clinics have been HLP003 offers the opportunity to significantly growing in the U.S. reduce treatment burden Approximately 8,000 existing Interventional Psychiatry clinics with capacity • 5300 SPRAVATO 1 clinics • 750 ketamine - on
Slide 8: HLP003
HLP003 Deuterated Oral NSA Adjunctive Treatment of MDD 8
Slide 9: MDD: Leading Contributor to Mental Health Patient Burden
MDD: Leading Contributor to Mental Health Patient Burden >300M 1 50 - 75% 4 persons worldwide with MDD of MDD patients also have anxiety symptoms >21M 2 2 out of 3 5 persons with MDD in the US patients do not experience relief with standard of care 20x Up to 38% increased suicide risk for an individ
Slide 10: Why Adjunctive Treatment Matters in MDD
Why Adjunctive Treatment Matters in MDD ] MDD in U.S .1,2 Benefits of adjunctive treatment: 21Madults ✓ Begin treatment immediately MDD excluding contraindications ✓ Prevent withdrawal symptoms 17M ✓ Remove barriers to treatment transition ✓ Build on benefits of background medications Moderate to se
Slide 11: HLP003 Advantages vs. Psilocybin
HLP003 Advantages vs. Psilocybin 1 • Removal of metabolic step and deuteration potentially increase efficiency of delivery, Optimized Delivery decrease drug load, and reduce PK and PD variability • Stable formulation and convenient oral capsule • Shifts in metabolism may reduce drug interaction risk
Slide 12: Deuterated Psilocin Offers Several Advantages
Deuterated Psilocin Offers Several Advantages 1 Advantages of Psilocybin Psilocin Deuterated Psilocin (HLP003) Inactive Prodrug Active Metabolite Dephosphorylation Deuteration *See Footnote 2 Bypasses first metabolic step ✓ Increasing efficiency of delivery ✓ Decreasing drug load • Slow onset • Shor
Slide 13: Shift in Metabolism May Reduce Drug Interaction Risk
Shift in Metabolism May Reduce Drug Interaction R isk 1 Psilocin is Metabolized into Inactive Breakdown Products PsilocybinPsilocybin 20 mg 20 mg (n=32) 2 HLP003 10 mg (n=4) 3 Psilocin AUC inf (ng*h/ml) AUCinf(ng*h/ml) Monoamine Glucuronidation Oxidase Psilocin Psilocin - 4 - HIAA HLP003 Psilocin -
Slide 14: Faster & Higher Brain Penetration than Psilocybin in Rodent Studies
F aster & Higher B rain P enetration than Psilocybin in Rodent S tudies 1,2,3 Potential to Limit Off - Target Potential for Faster Onset of Clinical Effects Potential for Better Efficacy AEs in the Periphery Time to Peak Concentration (n=15) Brain Exposure (n=15) Brain to Plasma Ratio (n=15) 21% 38%
Slide 15: Deuteration Translates into a Desirable PK Profile in Phase 1/2
Deuteration Translates into a Desirable PK Profile in Phase 1/2 1 mg (n=3) PK Benefits of HLP003 3 mg (n=3) 8 mg (n=6) 10 mg (n=3) ✓ Rapid absorption Plasma Concentration 12 mg (n=24) 16 mg (n=10) ✓ Short half life ✓ Good tissue distribution ✓ Low variability in PK ✓ Dose proportional increases in C
Slide 16: HLP003 Delivers Plasma Levels Higher than Psilocybin in Phase 1/2
HLP003 16 mg Delivers P lasma L evels Higher than 25 mg of Psilocybin in Phase 1/2 Psilocin vs. HLP003: C max Psilocin vs. HLP003: AUC inf 16 mg HLP003 delivers a 16 mg HLP003 delivers an AUC inf (ng*h/ml) 1.5x C max 1,2 1.5x higher vs. 25 2.5x AUC 1,2 2.5x higher vs. 25 mg C max (ng/ml) higher high
Slide 17: Favorable Pharmacodynamic Profile in Phase 1/2
Favorable Pharmacodynamic P rofile in Phase 1/2 Potentially Faster Onset of Clinical Effects Higher Intensity of Clinical Effects Self - Reported Any Drug Effects Self - Reported Any Drug Effects 100 100 90 Any Drug Effect (Mean + SEM) 80 80 Any Drug Effect 60 70 40 60 20 50 25mg HLP003 16 mg 0 2 4
Slide 18: Reproducible Pharmacodynamic Effects
Reproducible Pharmacodynamic Effects Self Reported Any Drug Effect Score (Indicator of Subjective Drug Effect) 1 16 mg cohort in Phase II study 2,3 Benefits of HLP003 Day 1 (N=9) Day 22 (N=9) 100 100 ✓ Effects reproducible with Effect (VAS) Effect(VAS) 75 75 DrugScore repeated dosing DrugScore ✓ Acu
Slide 19: HLP003 Program Overview
HLP003 Program Overview Positive 12 - month Phase 2 Results in MDD (2 doses – 16 mg) • Mean ~23 - point reduction in Montgomery - Asberg Depression Rating Scale (MADRS) Sustained improvements in scores from baseline at 12 months (average baseline MADRS was ~32) following 2 doses depression symptoms
Slide 20: HLP003: Phase 2a Trial Design in MDD
HLP 003: Phase 2a Trial Design in MDD 1,2 Screening Treatment Period Optional Open Label Period Up to 4 weeks Day 1 Week 3 Week 6 4 months 12 months HLP003 HLP003 Placebo HLP003 Phase 1: Single ascending dose study (1 - 10 mg), n=12 Key Inclusion Criteria: ✓ Moderate to severe MDD (MADRS ≥ 21) Phase
Slide 21: Large Improvement in Depression Symptoms After Single Dose of HLP003
Large Improvement in Depression Symptoms After Single Dose of HLP003 1 ±SD) MADRS change from baseline, mean ( Placebo Primary Effect Dose1 p-value (n=9) Endpoint* size Improvement in symptoms 12 mg -14.11 2.31 0.0001 16 mg -12.99 2.54 0.0080 HLP003 16 mg (n=9) *Primary endpoint: LS - means 2 differ
Slide 22: HLP003: Sustained Improvements in Depression Symptoms at 12 Months
HLP003: Sustained Improvements in Depression Symptoms at 12 Months 1 MADRS reduction from baseline Response and Remission 16 mg – 2 doses 16 mg – 2 Doses % Responders % Remitters 100 0 100 ±SD) -5 80 75 75 75 71 71 -10 MADRS change from baseline, mean ( Improvement in symptoms D21 57 -15 60 -14.6 D4
Slide 23: Phase 3 PARADIGM Program Overview
Phase 3 PARADIGM Program Overview The pivotal program will consist of 2 studies plus an extension 1,2,3 : Study design • APPROACH: Two - arm study of two 16 mg doses of HLP003 vs. placebo aligned with FDA • EMBRACE: Three - arm study with two 16 mg doses, 8 mg doses, and a placebo arm guidance and t
Slide 24: PARADIGM: HLP003 Phase 3 Pivotal Program in MDD
PARADIGM: HLP003 Phase 3 Pivotal Program in MDD Day 1 Week 3 Week 6 Week 12 Dose 1 Dose 2 Primary Secondary endpoint 1 endpoint 2 APPROACH 16 mg 16 mg Responders HLP003 - 002 (n = 220) Relapse EXTEND Randomized 1:1 Placebo HLP003 - 004 Placebo 16 mg 16 mg End of study Long - term extension Relapse s
Slide 25: HLP004
HLP004 Deuterated Intramuscular NSA Treatment of GAD 25
Slide 26: High Patient Burden and Persistent Treatment Gaps in GAD
High Patient Burden and Persistent Treatment Gaps in GAD Create a Clear Opportunity for Innovation Significant Unmet Need in GAD Current Treatments Continue to Fail GAD Patients >20M ▪ 2/3 of GAD patients experience no relief >300M 2 with initial SoC treatment 7 persons worldwide with persons with G
Slide 27: HLP004's Emerging Best-in-Class Profile
HLP004’s Emerging Best - in- Class Profile Positive Phase 1 and Phase 2 Results in Moderate - to - Severe Generalized Anxiety Disorder Rapid, Robust Clinically meaningful and statistically significant ~10 - point HAM - A reduction at 6 Treatment Effect weeks in both active doses (2 mg and 20 mg) wit
Slide 28: Comprehensive Studies Characterizing DMT Pharmacological Properties
Comprehensive Studies Characterizing Dimethyltryptamine (DMT) Pharmacological Properties Study Key Findings Phase 1/2a study with IV DMT in moderate to severe Rapid and durable antidepressant and anxiolytic effects after single MDD (no SSRIs) 1 administration Phase 1 IV/IM study 1 Characterized safe
Slide 29: HLP004 Designed To Improve Upon IV DMT
HLP004 Was Designed To Improve Upon IV DMT To Deliver Rapid & Durable Symptom Relief Via Single Treatment Cycle Limitations of IV DMT HLP004 Improved Pharmacokinetic Properties vs. IV DMT • Unfavorable pharmacokinetics: rapid peak, rapid elimination resulting in short - lived, intensive <30 min expe
Slide 30: Phase 1 Dose Ranging Trial: Linear, Predictable Pharmacokinetics
Phase 1 Dose Ranging Trial Linear, Predictable and Reproducible Pharmacokinetics and Robust Pharmacodynamics Emotional Breakthrough Inventory (EBI) 1 Pharmacokinetics • Emotional Breakthrough Concentration (ng/mL) as measured using EBI is HLP004 Plasma %participants scoring ≥60% considered predictiv
Slide 31: Intramuscular Administration Permits Rapid Discharge Within ~3 Hours
Phase 1 Dose Ranging Trial Intramuscular Administration Permits Rapid Discharge Within ~3 Hours N=10 N=6 Acute effects last 90 minutes only 3 N=6 N=6 Ready for discharge within ~3 hours N=6 allowing for access into existing N=6 SPRAVATO 4 treatment paradigm LSD2 Time to Discharge 1 (Hours ; Mean + S
Slide 32: HLP004 Phase 2 Topline Data in Generalized Anxiety Disorder
HLP004 Phase 2 Topline Data in Generalized Anxiety Disorder 32
Slide 33: HLP004 Phase 2 Signal Detection Study in GAD
Phase 2 Signal Detection Trial HLP004 Phase 2 Signal Detection Study in GAD Double - blinded Phase 2 study of HLP004 as an adjunctive treatment on top of SOC for patients suffering with GAD HLP004 Phase 2 Clinical Trial Design • Age 18 –65 with diagnosis of GAD Key • Currently on stable dose of Incl
Slide 34: HLP004 Phase 2 Baseline Characteristics
Phase 2 Signal Detection Trial HLP004 Phase 2 Baseline Characteristics Demonstrate Real World Treatment Paradigm 20 mg 2 mg Overall Characteristic (n=25) (n=11) (n=36) Key Takeaways ▪ Moderate - to - severe patients (average HAM -A Age (years); Mean (SD) 34.6 (9.92) 42.4 (12.14) 37.0 (11.08) lower t
Slide 35: HLP004 Demonstrated Rapid and Profound Effects over SoC
Phase 2 Signal Detection Trial HLP004 Demonstrated Rapid and Profound Effects over SoC, with Effects Sustained Through at Least 6 Months Anxiety Symptom Improvement Meets Durable Anxiety Symptom Improvement Primary Endpoint at 6 Weeks Through 6 Months Treatment Period change from baseline HAM - A LS
Slide 36: Single HLP004 Treatment Cycle Resulted in ~70% Responders at 6 months
Phase 2 Signal Detection Trial Single HLP004 Treatment Cycle Resulted in ~70% Responders and ~40% Remitters at 6 months Responders and Remitters at 6 Weeks Responders and Remitters at 6 Months % Responder or Remitter % Responder or Remitter N=12/18 No observed regression N=13/22 to baseline unlike p
Slide 37: Impact of HLP004 in Real World Clinical Setting
Impact of HLP004 in Real World Clinical Setting Illustrative Benefit of Adjunctive Treatment in GAD 22.4 * Illustrative data only; from multiple Adjunctive HLP004 different trials, study designs; Effect therefore, not like - for - like comparison + 10.4 Approved Monotherapies 13.4 12.4 12.5 11.9 10.
Slide 38: HLP004's Emerging Best-in-Class Profile As a Short Acting Treatment
HLP004’s Emerging Best - in- Class Profile As a Short Acting Treatment for Psychiatric Conditions Fits Durability with Acute 2 Single Patient Ready to SPRAVATO’s Single Intellectual Subjective Treatment Population in AEs Discharge Commercial Treatment Property Effects Cycle Trial Model Cycle 100% HL
Slide 39: Leadership Team with Proven Record of Regulatory and Commercial Success
Leadership Team with Proven Record of Regulatory and Commercial Success Leadership Michael Halstead Eric So Amir Inamdar MBBS, Alex Nivorozhkin, Ph.D. Aaron Bartlone George Tziras Paul Glavine Chief Executive Officer Co - Founder & DNB(Psych), F FPM Chief Scientific Officer Chief Operating Officer C
Slide 40: Leading the Development of NSAs
Leading the Development of NSAs 1,2 Two proprietary clinical programs, HLP003 and HLP 004, targeting MDD and GAD with positive Phase 2 1 safety and efficacy results Lead program HLP003 has been granted U.S. Food and Drug Administration Breakthrough Therapy 2 Designation and is in Phase 3 studies for
Slide 41: Thank You
Thank You Nasdaq: HELP | Cboe CA: HELP Contact: irteam@helus.com 41
Slide 42: References
References SLIDE 5 SLIDE 7 1) https://www.nimh.nih.gov/health/statistics/major - depression 1) SPRAVATO is a registered trademark of JOHNSON & JOHNSON Corporation, USA. 2) Vasiliadis, H. M., Lesage, A., Adair, C., Wang, P. S., & Kessler, R. C. (2007). Do Canada 2) https://www.grandviewresearch.com/i
Slide 43: Appendix
Appendix HELUS PHARMA
Slide 44: Favorable Safety Profile of HLP003
Favorable Safety Profile of HLP003 • No AEs were reported at the 12 - month follow up • No reports of suicidal ideation or behavior or any long - term adverse sequelae In the short - term study: • No SAEs and no participant discontinued the study due to an AE • Most common AEs were nausea, elevated
Slide 45: HLP004: Generally Well-Tolerated, Adverse Events were Transient
Phase 2 Signal Detection Trial HLP004: Generally Well - Tolerated, Adverse Events were Transient, with No Drug Related Serious Adverse Events Recorded SOC Psychiatric Disorders All AEs were mild/moderate 20 mg 2 mg Total AEs > 10% across all N (%) N (%) N (%) participants No severe or serious AEs 12
Helus Pharma (Cybin Inc.) — Investor Presentation (August 2026) on 6ix